Work

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Year: 2018

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2018-99-111529

Authors: Peter Westervelt, Gail J. Roboz, Jorge E. Cortes, Hagop M. Kantarjian, Sangmin Lee, Michael P. Rettig, Tae H. Han, Jeanmarie Guenot, Eric J. Feldman, John F. DiPersio

Institutions: Washington University in St. Louis, Cornell University, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4206277904

Cites:

Cited by: 22

Related to: 10